Sandra González is an associate in the Litigation practice of Paul Hastings and is based in the firm’s New York office. Her practice focuses on representing life sciences companies, of all sizes and throughout the product lifecycle, in connection with internal and government investigations and advising clients on day-to-day U.S. and OUS compliance matters.
Ms. González has particular experience counseling life sciences companies on a variety of matters, including: U.S. fraud and abuse laws; promotional activities; interactions with healthcare professionals (“HCPs”), patients, and patient advocacy organizations (“PAO”); industry standards and best practices; and anti-corruption and anti-bribery (“ABAC”) laws, including the Foreign Corrupt Practices Act (“FCPA”) and the UK Bribery Act.
Legal and Regulatory Compliance Counseling
Investigations and White Collar Defense
Risk Assessments and Diligence
Foreign Language Capabilities
Paul Hastings Wins Law360 Life Sciences Practice Group of the Year
February 05, 2018
On the Heels of Significant FCPA Settlements, Past and Present Meet as Novartis Reaches FCA Settlements in Two Districts
July 16, 2020
Compliance in the Era of COVID-19 – Where and How Life Sciences and Health Care Companies Should Focus in the Era of Social Distancing
April 22, 2020
The Life Sciences Enforcement Zeitgeist: Will German Companies Withstand the Scrutiny?
November 06, 2017
Against the Backdrop of a ‘National Emergency,’ Are Opioid Cos. Ready for the Enforcement Spotlight?
September 06, 2017
Against the Backdrop of a ‘National Emergency,’ Are Opioid Manufacturers Ready for the Enforcement Spotlight?
August 25, 2017
Recognized as Law360 Practice Group of the Year in Life Sciences
Paul Hastings was named as a Practice Group of the Year in Life Sciences by Law360. The article noted Paul Hastings’ undefeated track record in life sciences cases at the Patent Trial and Appeal Board, including victories on behalf of Acorda Therapeutics, which won four inter partes reviews against Kyle Bass’ Coalition for Affordable Drugs. Law360 also highlighted the representation of Galena Biopharma in a civil-only settlement resolving investigations regarding Galena’s past promotional practices for Abstral, a rapid onset opioid product. The winners were chosen from nearly 750 submissions, and are recognized as "firms that racked up victories in litigation and closed the big deals to make their mark among clients and throughout the legal industry."
February 01, 2018